Europe psychedelic drugs market is projected to register a CAGR of 11.5% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation:
Europe Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) Country (Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Belgium, Lithuania, Rest of Europe) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the Europe psychedelic drugs market are:
Growing acceptance of psychedelic drugs for treating depression
Increasing prevalence of depression and mental disorders
Stringent regulations for psychedelic drugs
Market Players:
The key market players for Europe psychedelic drugs market are listed below:
Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
Hikma Pharmaceuticals PLC
COMPASS
Verrian
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Jazz Pharmaceuticals, Inc.
Avadel
Celon Pharma S.A.
NeuroRx, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE PSYCHEDELIC DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE OF PSYCHEDELIC DRUGS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 EPIDEMIOLOGY
6 REGULATORY FRAMEWORK: EUROPE PSYCHEDELIC DRUGS MARKET
6.1 REGULATORY SCENARIO IN INDIA
6.2 REGULATORY SCENARIO IN UAE
6.3 REGULATORY SCENARIO IN AFRICA
6.4 REGULATORY SCENARIO IN THE U.S.
6.5 REGULATORY SCENARIO IN BRAZIL
6.6 REGULATORY SCENARIO IN THE U.K.
7 PIPELINE ANALYSIS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION
8.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS
8.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH
8.1.4 ONGOING CLINICAL TRIALS
8.1.5 RISE IN PRODUCT APPROVALS
8.2 RESTRAINTS
8.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS
8.2.2 HIGH COST OF PSYCHEDELIC DRUGS
8.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS
8.3 OPPORTUNITIES
8.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS
8.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY
8.3.3 UPCOMING REHABILITATION CENTERS
8.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS
8.4 CHALLENGES
8.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS
8.4.2 RISE IN ALTERNATIVES
8.4.3 OTHER TREATMENT OPTIONS
9 COVID-19 IMPACT ON EUROPE PSYCHEDELIC DRUGS MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 EUROPE PSYCHEDELIC DRUG MARKET, BY SOURCE
10.1 OVERVIEW
10.2 SYNTHETIC
10.3 NATURAL
11 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE
11.1 OVERVIEW
11.2 EMPATHOGENS
11.3 DISSOCIATIVES
11.4 OTHERS
12 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS
12.1 OVERVIEW
12.2 GAMMA-HYDROXYBUTYRIC ACID
12.3 KETAMINE
12.4 PSILOCYBIN
12.5 OTHERS
13 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPPLICATION
13.1 OVERVIEW
13.2 NARCOLEPSY
13.3 TREATMENT RESISTANT DEPRESSION
13.4 MAJOR DEPRESSIVE DISORDER
13.5 OPIATE ADDICTION
13.6 POST-TRAUMATIC STRESS DISORDER
13.7 OTHERS
14 EUROPE PSYCHEDELIC DRUG MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 INHALATION
14.4 INJECTABLE
15 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOMECARE
15.5 OTHERS
16 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 ONLINE PHARMACY
17 EUROPE PSYCHEDELIC DRUGS MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 U.K.
17.1.3 FRANCE
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 POLAND
17.1.8 SWITZERLAND
17.1.9 NETHERLANDS
17.1.10 HUNGARY
17.1.11 AUSTRIA
17.1.12 NORWAY
17.1.13 IRELAND
17.1.14 BELGIUM
17.1.15 LITHUANIA
17.1.16 REST OF EUROPE
18 EUROPE PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT
20 COMPANY PROFILE
20.1 JAZZ PHARMACEUTICALS, INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 PFIZER INC.
20.3.1 REVENUE ANALYSIS
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 VERRIAN
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENT
20.5 AVADEL
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 RECENT DEVELOPMENTS
20.6 CELON PHARMA S.A.
20.6.1 COMPANY SNAPSHOT
20.6.2 PIPELINE PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 COMPASS
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENTS
20.8 F. HOFFMANN-LA ROCHE LTD
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 HIKMA PHARMACEUTICALS PLC
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.10 NEURORX, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 PHARMATHER INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 USONAINSTITUTE.ORG
20.12.1 INSTITUTE SNAPSHOT
20.12.2 PIPELINE PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
Segmentation
Short Description
Europe Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) Country (Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Belgium, Lithuania, Rest of Europe) Industry Trends and Forecast to 2028
Market Definition
Psychedelic drugs involve various types of chemical substances including LSD and chemical extracted from plants. Psychedelic drugs have the ability to change or enhance the senosory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences. Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.
Market Segmentation
The psychedelic drugs market is segmented into seven notable segments which are based on the source, type, drugs, application, route of administration, end user and distribution channel.
On the basis of source, the psychedelic drugs market is segmented into synthetic and natural
On the basis of type, the psychedelic drugs market is segmented into dissociatives, empathogens and others
On the basis of drugs, the psychedelic drugs market is segmented into gamma-hydroxybutyric acid, ketamine, psilocybin and others
On the basis of application, the psychedelic drugs market is segmented into narcolepsy, treatment resistant depression, post-traumatic stress disorder, major depressive disorder, opiate addiction and others
On the basis of route of administration, the psychedelic drugs market is segmented into oral, inhalation and injectable
On the basis of end user, the psychedelic drugs market is segmented into hospitals, specialty clinics, homecare and others
On the basis of distribution channel, the psychedelic drugs market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy
Market Players
The key market players for Europe psychedelic drugs market are listed below:
Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
Hikma Pharmaceuticals PLC
COMPASS
Verrian
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Jazz Pharmaceuticals, Inc.
Avadel
Celon Pharma S.A.
NeuroRx, Inc.
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
